 As paclitaxel has been noted to be active in ovarian cancer and other malignancies, it seems reasonable to evaluate its utility for endometrial cancer. Accordingly, single agent paclitaxel was administered to 30 chemotherapy naïve patients with advanced or recurrent endometrial cancer. The overall response rate was 36 when patients received a 24-hour infusion of paclitaxel. Furthermore, paclitaxel given as a 3-hour infusion demonstrated a response between 27 to 37 in patients that had failed prior chemotherapy. 